Caris Life Sciences, Inc. (CAI) Balance Sheet

The swing from negative to positive equity over five quarters appears driven less by operating earnings than by balance sheet restructuring, since retained earnings remain near -$2.5B throughout. This suggests the equity rebuild may rest on capital raises or debt conversion rather than retained profitability. Investors should monitor whether equity continues to be supported by external financing rather than earnings.

The reduction from $2.3B of debt in 2021 to under $70M now implies that the prior leveraged structure was substantially eliminated. The current low leverage may reflect deliberate deleveraging, though the reported figures do not disclose the terms or sources of the repayment. Refinancing risk appears limited at present, but this assessment depends on the accuracy of the reported debt figures.

A current ratio near 6.7 suggests the company can meet short-term obligations many times over, a meaningful buffer given recent negative operating earnings. However, the cash balance declined from $821.1M in 2026Q1 to $665.3M in 2026Q3, suggesting ongoing cash consumption. The pace of that decline warrants monitoring against the company's operating cash burn.

The growth in PP&E alongside a stable goodwill balance suggests the expansion reflects investment in laboratory and sequencing infrastructure rather than acquisitions. Goodwill at $19.3M is modest relative to total assets, limiting impairment exposure. The asset mix points to an operationally intensive business model, which implies ongoing capital needs.